A B S T R A C T The mechanism of drug-induced displacement of bilirubin from the blood into tissues was studied. 
INTRODUCTION
A number of drugs, if given to newborn children with unconjugated hyperbilirubinemia, may displace bilirubin from its binding to plasma albumin, with the possible effect that the pigment enters the central nervous system, causing kernicterus or various late manifestations of brain damage. Sulfisoxazole is known to exert such an effect clinically (1, 2) . This and other sulfonamides may precipitate kernicterus in hyperbilirubinemic ani-mals (3, 4) and show a bilirubin-displacing effect in vivo (3, 5) and in vitro (6, 7) . Salicylate, given to humans (8) and to Gunn rats (9, 10) , causes a drop of serum bilirubin concentration, presumably due to displacement of the pigment to extravascular receptors. Large doses of fatty acids, infused to a child, resulted in a marked increase of the concentration of unbound bilirubin (11) .
Some investigators have doubted the danger of giving sulfonamides to icteric newborns (12, 13) , and a competitive effect of salicylate has been questioned by Thaler and Schmid (14) . The latter authors, invoking a different principle, warn against the use of acetylsalicylic acid in hyperbilirubinemic patients because this drug has been shown to acetylate serum albumin (15) , impairing its affinity for nonpolar anions. This uncertainty calls for investigation of the mechanism involved in displacement of bilirubin with drugs. In the present paper, the problem is elucidated by kinetic studies of oxidation of free bilirubin with hydrogen peroxide and peroxidase. A method for quantitative assessment of displacing effects is proposed.
As a basis for calculation of the effect of a competing drug, a model is defined by the following five assumptions: (a) Free, monomer bilirubin anion is present in solutions containing bilirubin and a molar excess of human serum albumin at neutral pH. The free bilirubin concentration is very low and cannot be determined by conventional means. Relative values of the free bilirubin concentration can be measured by the rate of oxidation with hydrogen peroxide and peroxidase. (b) One molecule of bilirubin is bound reversibly to one high-affinity site on serum albumin. (c) The free bilirubin concentration remains small, compared to the total. (d) One molecule of the drug is bound competitively to the bilirubin-binding site. (e) Additional molecules of the competitor may be bound to other sites on albumin, without interfering with binding of bilirubin.
It will be shown that this model is sufficient to describe the experimental findings, and the validity of the assumptions will be discussed.
METHODS
Oxidation of bilirubin with hydrogen peroxide and peroxidase follows Michaelis-Menten kinetics (16) . Km for bilirubin at pH 8.2 is 8 X 10' M and less than 2 X 10' M for hydrogen peroxide. It is not possible to determine these constants at pH 7.4, due to the low solubility of bilirubin in neutral solutions, but they are unlikely to be several orders of magnitude different from the values at pH 8.2. This means that the rate of oxidation is proportional to the bilirubin concentration in the nanomolar range and is independent of the hydrogen peroxide concentration when this is of the order of 100 ,uM. A convenient principle is hereby available for relative determinations of free bilirubin concentrations in equilibrium mixtures. The processes involved are BP B + P, L X where B, P, and X, are bilirubin, albumin, and oxidation product, respectively. The rate of the total process, conversion of the bilirubin-albumin complex to free albumin and the oxidation product, is proportional to the equilibrium concentration of free bilirubin if the following two conditions are fulfilled: (a) the free bilirubin only is oxidized, while bound bilirubin is protected, and (b) the velocity of the dissociation of bilirubin from albumin is high compared to the oxidation, so that the latter process is rate determining. It has previously been found by Jacobsen (17) that the rate of oxidation varies with the ratio of bilirubin to albumin in accordance with these assumptions, and further evidence for their validity is reported in the present paper ( Figs. 2 and 3 [BP]., p. (1) bo p Experimental determinations of KD were based on this equation. A reaction mixture was prepared, containing bilirubin and human serum albumin in a molar ratio of 1:2. The velocity of oxidation with hydrogen peroxide and peroxidase was determined with and without added drug. The ratio of these velocities was equated with the ratio of free bilirubin concentrations, b/b,.
The free drug concentration in Eq. 1 is generally not known. If enough of the drug is added to provide a considerable excess over the amount bound to albumin, we can use the total concentration as an approximation of the free and obtain -= KDD + 1, bo (2) which is valid when the drug concentration is large, compared to that of albumin (see Discussion).
Determination of the initial rate of the oxidation process from the slope of the progress curve as soon as possible after addition of the enzyme was found to be less reproducible than determination of the time taken for a certain fraction of the total change of optical density. In experiments with varying enzyme concentration and with several drugs, it was found that the ratio of such time periods with and without added drug was independent of whether the fraction 0. (4) which is derived from Eqs. 2 and 3, if the velocity is proportional to the enzyme concentration (Fig. 3) .
The left side of Eq. 4 The concentration of free bilirubin was about 0.015 MU, (17) increasing on addition of a strongly displacing drug beyond the limit of solubility, which is about 0.1 MuM (24) .
In most cases, the pigment remained in a supersaturated solution. Colloid precipitation could be discovered by a progressive decrease of maximal light absorption and broadening of the spectrum. In selected cases, the stability of the solution was checked by measuring light scattering (23 Drugs of low solubility were added in alcoholic solution to the buffered bilirubin-albumin solution. Ethanol, 1% vol/vol, influenced the oxidation rates only slightly. In critical cases, tests were done with low concentrations of albumin, 6 MM, and bilirubin, 3 MM, in a 4-cm cell, and peroxidase concentration 2.4 nM or less (Fig. 4 , phenyl salicylate). The low concentration of bilirubin did not give rise to instability when albumin was present.
The suitability of the enzymatic system and the albumin preparation was tested by examining the variation of the oxidation velocity with albumin concentration (Fig. 2 ).
Some albumin preparations, stored dry for about 1 yr at 4°C, gave increased velocities at high albumin concentrations. Defatted albumin was more stable during storage than albumin with natural fatty acids.
The reproducibility of the oxidation velocity determinations without added drug corresponded to a standard deviation of about ±3%o, increasing to the order of ±5%c in the presence of a strongly competing drug. (16) . The shape of the curve indicates that intermediate products with high optical density are not formed or are short-lived. Oxidation of bilirubin with hydrogen peroxide and peroxidase in this respect seems to be different from photooxidation, which proceeds through strongly colored intermediates (26) (27) (28) . Monitoring of the optical density at 455 nm apparently is suitable for observing the progress of the enzymatic oxidation.
Exposure of the bilirubin-albumin mixture to sunlight caused a slight decrease of the light absorption spectrum (Fig. 1, left, In the absence of a competing drug, the velocity of oxidation of bilirubin with hydrogen peroxide and peroxidase in mixtures with albumin decreases with increasing albumin concentration. This variation was examined and the results are pictured in Fig. 2 Fig. 3 therefore intersects the ordinate axis slightly above the origin. It can easily be shown that this line is the expected result if dissociation occurs as a first-order process, with a velocity constant of 3 min'. This shows that the dissociation is so fast that the oxidation can be regarded as rate determining with good approximation, if the time taken for 0.2 of the total oxidation is kept higher than 2 min.
At low enzyme concentrations (not shown in the figure) the range of proportionality extends below 20 pM peroxidase. The enzyme is remarkably stable even at these extreme dilutions.
Competitive effect of drugs. The competitive effect of 20 substances was examined. The method proved applicable in all cases. Two cationic drugs, gentamicin and polymyxin B, precipitated bilirubin in the absence of albumin. These substances did not change the rate of oxidation of bilirubin when albumin was present, and it was accordingly possible to ascertain their noncompetitive nature. No other complications were encountered.
15 of the drugs showed measurable competition with bilirubin. In all cases a linear relationship was obtained for the velocity as a function of drug concentration (Fig.  4) , in agreement with the proposed model.
It is concluded that certain drugs decrease the binding of bilirubin to its high-affinity site on human serum very small compared to that of bound. In the equilibrium equation, the total bilirubin concentration could thus be used in place of the bound. This gives B X KB P-B (5) If the velocity of the oxidation process is proportional to the free bilirubin concentration b, and B and KB are constant, we would expect to find a velocity proportional to 1/(P-B). As seen in Fig. 2, this Variation of the oxidation velocity with the enzyme concentration was examined, with constant concentrations of bilirubin and albumin (Fig. 3) . If the dissociation of bilirubin from the complex with albumin is very fast, compared to the oxidation, so that the latter process is rate limiting, the velocity should be proportional to the enzyme concentration, which means that to.2 should be proportional to the inverse enzyme concentration, FIGURE 5 Light absorption spectra of bilirubin-albumin, 15/30 /AM, in phosphate buffer, pH 7.4, in the presence of polymyxin B, concentrations 0, 0.4, 0.7, and 1.0 mM. Cell, albumin. The increase of free bilirubin concentration may be described in terms of competitive binding of the drug to this site. The binding constants are seen in Table I .
Binding of drugs to other sites. Certain ligands may bind to albumin without interfering with bilirubin binding. N-acetyl-L-tryptophan binds to one site on human serum albumin at pH 7.4, with the association constant 3 X 10' M-1 (29) . The affinity for the bilirubin site is low, KD = 1.1 X 108 M' (Table I) . This seems to indicate that the first molecule of acetyltryptophan is bound to a locus other than the first site for bilirubin.
Shifts of the spectrum of bilirubin-albumin were seen with most of the drugs tested, even when the free bilirubin concentration remained constant. An example of this is shown in Fig. 5 . The spectrum of a bilirubinalbumin solution, 15 and 30 iM, is gradually changed by addition of polymyxin B, 0.4-1 mM. The shoulder at 420 nm is decreased and the maximum at 460 nm is increased. Some drugs (salicylate and related substances) caused a shift in the opposite direction. Polymyxin B and several other drugs apparently are bound to albumin at sites other than the high-affinity site for bilirubin. It is interesting to note that binding of polymyxin B to one site influences the light absorption spectrum of bilirubin, bound to a different site, without causing a change in the affinity of the bilirubin-albumin bond.
Besides the competitive binding of drugs demonstrated above, another type of liganding of some drugs takes place at sites distinct from the first site for bilirubin. This does not seem to influence the affinity of bilirubin for the first site. A third, hypothetical, type of liganding, in which a drug bound to one site decreases or increases the affinity of bilirubin on another site, would give curved or sigmoid-shaped relationships and has not been demonstrated in the present material.
DISCUSSION
The experimental principle. Evaluation of kernicterus-promoting effects of drugs, as caused by interaction with binding of bilirubin to albumin, cannot be done directly on newborn humans, and the use of experimental animals is complicated by species variation of binding patterns for drugs and bilirubin to serum albumin. In vitro studies of binding interactions must be relied upon and the effects in the fetus or newborn child has to be inferred from the in vitro observations. For this purpose, knowledge of the mechanism of interaction, whether reversible, competitive, etc., is essential. Furthermore, a quantitative description of the interaction is necessary.
A drug not bound to albumin cannot function as a competitor. Binding is a necessary but not a sufficient condition for a bilirubin-displacing effect, since bilirubin and drug may ligand to distinct sites on the albumin molecule. This seems in fact to take place with some drugs. It is consequently necessary to study the shifts of binding equilibrium caused by the drug, and this again means that knowledge of the physical state of bilirubin in solution is prerequisite.
At a pH of about 8-9, bilirubin is soluble in water and is present as a monomer anion in equilibrium with its dimer (25) . The dissociation constant is of the order of 10-' M, independent of pH, indicating that bilirubin in the micro-or nanomolar range is predominantly monomer. At pH 7.4, the solubility is very low and colloid aggregation tends to take place at concentrations higher than about 0.1 /M (24), although higher concentrations may remain in a metastable, supersaturated solution for some time. In the presence of serum albumin, reversible binding of bilirubin takes place to one high-affinity and a few weaker sites (17, 23) . According to general concepts of binding equilibrium, this should result in a certain concentration of unbound bilirubin in the solution. At a ratio 1: 2 of bilirubin to albumin, the free bilirubin concentration is very low, probably of the order of 10 nM (17), and in any case very small compared to the concentration of bound pigment. Under these circumstances it is not possible to measure the free bilirubin concentration by conventional, spectroscopic means, and evidence for its existence can only be obtained indirectly. The reality of such small, free, monomer bilirubin concentrations is supported by the findings in the present paper of predicted oxidation velocity relations to the concentration of albumin (Fig.  2 ) and competing drugs (Fig. 4) . Various experimental principles have been used for demonstration of the bilirubin-displacing effect of drugs. A shift of light absorption spectrum takes place when bilirubin is bound to albumin. This, however, cannot be used as a basis for studying binding equilibria at the first site, due to the very low ratio of free to bound pigment. For the same reason, it is also not possible to utilize the fact that bound bilirubin shows a fluorescence while the free does not. The same is true for the optical rotation, seen with bound bilirubin, but not with the free. All these principles would be further complicated by shifts of the spectra that occur on binding of new ligands, drugs, to other sites on the bilirubin-albumin complex (Fig. 5) .
Separation of the free bilirubin by ultrafiltration, equilibrium dialysis, or ultracentrifugation (30), followed by spectrophotometric determination, gives disappointing restlts due to instability of bilirubin in very dilute solutions and a tendency of the pigment to adhere to membranes and glass surfaces. Attempts were made in the author's laboratory to use 'C-labeled bilirubin in an ultracentrifugation technique. It was found that a small, nearly constant, fraction of the radioactivity was present in the protein-free supernate. This could not be identified as bilirubin and was thought to originate from decomposition, probably due to light (26) .
Observation of bilirubin displacement to an adsorbent, cholestyramine (9, 28) or Sephadex (12, 19, 31, 32) , or to erythrocytes (7, 8, 33, 34) (35) , steroids (36) , detergents (37) , or calcium ions (36) are bound to serum albumin. It is, accordingly, necessary with each displacing substance to examine whether a linear relationship of oxidation velocity and drug concentration exists at levels of the latter considerably higher than that of albumin, to establish a simple, competitive mechanism of displacement.
Description of the mechanism of displacement as a simple competition between one molecule of bilirubin and one of the drug for a specific site on the albumin molecule opens the possibility of assessing the effect of each drug by its binding constant, KD, to this locus.
Knowledge of this constant and of the free drug concentration in plasma defines the relative increase of free bilirubin concentration caused by the drug, according to Eq. 1. It is not necessary to know the affinity of bilirubin for binding to albumin.
Validity of the approximative assumptions. The experimental determination of KD by the peroxidase method is based on several approximations, namely: (a) The free bilirubin concentration is very small compared to the total; ( b) The free concentration of the competing drug is equal to the total; and (c) Bilirubin is bound to one site only.
The errors caused hereby in determination of KD are discussed in the following:
(a) In a solution containing 30 WM albumin and 15 uM bilirubin, the free concentration of the latter is equal to 1/KB, i.e., probably around 10 M. With a strong competitor at high concentration, it might appear possible to displace a major fraction of the bilirubin. This would result in smaller increases of oxidation velocity at high drug concentrations. The straight lines obtained in all cases, with three of the drugs up to free bilirubin concentrations as high as 50 times the original (Fig.  4 , methyl p-hydroxygenzoate, propyl p-hydroxybenzoate, phenylbutazone), confirm the validity of the assumption that the free bilirubin concentration is very small compared to the bound within this range of increase. (b) Eq. 1 is thus valid in all cases and may be written:
bo D (6) At high drug levels, the free concentration, d, approaches the total, D, Eq. 2 becomes valid, and the slope of the line approaches KD. At the other extreme, when D is small compared to the albumin concentration, the slope is smaller, KDd/D.
Let us first consider the deviation if the drug is bound strongly to one or a few sites. A curve is then obtained (Fig. 6a) , merging into a straight line with the slope KD at high drug concentrations. This straight line is shifted along the abscissa away from the ideal, by a certain concentration, e. The value of e is equal to the maximal concentration, nP -B., of bound drug, obtained at full saturation of all sites, where n is the total number of drug-binding sites, since the concentration, B, of these is occupied by bilirubin. A straight line, fitted through (0, 1) and the experimental points scattered along the curve, may be drawn through a point on the straight portion of the curve around the abscissa Dm../2, if Dina. is the highest concentration of the drug plotted in the graph. (Fig. 6a, dotted line) . The (Fig. 4) , diphenylhydantoin would be likely to show an especially large error. At a guessed n value of 4, KD would be determined as low as 0.475 times the true value. It is unlikely, however, that a corresponding curvature of the line should be masked by experimental scatter of the points. Actual errors are probably smaller. In case of doubt, the determination could be repeated with onefifth the concentrations of albumin and bilirubin, reducing the error to one fifth. This was done in case of diphenylhydantoin, but gave no significant change of the slope, (Fig. 7) . Typical errors in this category range about 1-10%.
If the drug is bound with low affinity to a high number of loci, in addition to the bilirubin site, it becomes impossible to attain drug concentrations high enough to fulfill the condition d D. This would be likely to result in a curved line, except in the extreme case when all sites remain largely unoccupied but are present in a high number, so that the total amount of bound drug becomes significant. (17, 23) , and may influence the determination of KD. The effect of a competing drug under the circumstances of the in vitro experiment may be described as a change of the binding constant for bilirubin to a lower, apparent value, KB(app) = KB!(KDd + 1), (7) derived in analogy with the apparent Michaelis constant of an enzyme-substrate in the presence of a competitive inhibitor. Corresponding relations hold for the secondary sites. If KD values of all sites are equal, it is seen that the free bilirubin concentration will vary with that of the drug in accordance with Eq. 1. The true value of KD is then obtained from the slope of the line. Problems arise when the KD of the primary site is much higher than that of the secondary, i.e. when the drug competes mainly or exclusively for the primary site. In this case, the apparent KB of the primary site may approach the values of the secondary loci, or the apparent affinities may even be reversed, with the result that major amounts of bilirubin are displaced to the secondary sites. Each site will then carry a smaller amount of bilirubin, and the free bilirubin concentration will be lower than predicted from Eq. 1. At low drug concentrations, the slope of the line will be close to KD for the primary site, provided that nearly all bilirubin is bound to this in the absence of a drug. At very high drug levels, the slope will approach the lowest KD value of any site, since all bilirubin finally will be displaced to the site where the drug has the least affinity (Fig. 6b) Total plasma albumin concn. 400 AM, plasma volume 100 ml, KB = 7 X 107 M-1, KD = 1.0 X 104 M-1.
Displacement to or from reservoirs other than plasma albumin and an arbitrarily chosen receptor is neglected.
reason for this may be that the affinity of bilirubin for the secondary sites is very much less than for the first. It is possible, however, that curvatures of the types shown in Fig. 6a 5 and to express it by the total plasma concentration D of the drug, 
when q is the fraction of the drug bound to plasma proteins. The numerical value may be calculated if KD is known and the free drug concentration needed for therapeutic effect or the total plasma concentration and degree of protein binding are specified.
The binding constants obtained for the four sulfonamides (Table I) indicate an increasing competition with bilirubin in the order sulfanilamide < sulfadiazine < sulfamethizole < sulfisoxazole. Bratlid (7) has examined the binding of bilirubin to erythrocytes in solutions with albumin after addition of these sulfonamides and has found that it is increased in the same order of efficiency. Sulfisoxazole at usual dosage gives a plasma level about 0.5 mM, 85% of which is protein bound. The maximal displacement factor, calculated from Eq. 8, is 2.4. At this blood plasma concentration, sulfisoxazole may thus cause an increase by a factor of 2.4 of the amount of bilirubin bound to a critical receptor, such as an area of the brain. These findings are consistent with the clinical experience of a displacing effect of sulfisoxazole (1, 2, 5) .
The mechanism of displacement with salicylate. Sodium salicylate is a fairly potent competitor, as seen from its KD value, 0.9 X 10' M-1. The degree of protein binding, however, is high at moderate plasma concentrations. According to Rudman, Bixler, and Del Rio (35) , two molecules of salicylate are bound to human serum albumin with a binding constant of 105 M'. Half-saturation of these sites is produced by moderate doses and gives a free plasma concentration of 10-' M of salicylate. The maximal displacement factor is 1.09, in agreement with the fact that clinical displacement has not been reported with this drug. Presumably, the first two molecules of salicylate are bound to human serum albumin without interfering with the bilirubin site. A following molecule of the drug, bound in a subordinate class of sites, competitively displaces bilirubin. Maximal dosage, giving a drug/albumin ratio of 3 or 4, would be expected to result in displacement. A decrease of bilirubin concentration in blood plasma has in fact been demonstrated after large doses of salicylate in the Gunn rat (9, 10) and in man (8) .
Thaler and Schmid (14) refer to the permanent acetylation of albumin with acetylsalicylic acid, demonstrated by Hawkins, Pinckard, Crawford, and Farr (15) , and warn against use of this drug in patients with unconjugated hyperbilirubinemia. This is based on the fact that acetylation of albumin decreases the affinity for certain anions. Jacobsen (40) has found, however, that acetylation of human serum albumin in vitro with acetylsalicylic acid did not change the affinity for bilirubin. One specific lysyl-amino group is attacked by acetylsalicylic acid and seems to be involved in the binding of fatty acids and tryptophan (41) , whereas bilirubin is bound to a different site. The competitive effect of acetylsalicylic acid as such is slight (Table I) , and large doses would be needed to produce displacing amounts of salicylate.
Clinical experience and observations from animal experiments and from kinetic studies in vitro can be explained by a simple, competitive mechanism of bilirubin displacement by drugs.
As stressed by Stern (42) , any drug used in the newborn should be examined for its ability to displace bilirubin from albumin. Even during pregnancy, a displacing drug may reach the fetus via the placenta and exert its effect in case of fetal hyperbilirubinemia. Similarly, passage of pharmaca with breast milk should be considered. At present, such testing is not required by official authorities but ought to be carried out for all drugs in current use and as a routine before licensing of new substances.
